Koelis’ Promap-FT software.
Koelis Announces New Products at American Urology Association (“AUA”) Meeting
11 mai 2022 08h00 HE | Koelis
GRENOBLE, France and PRINCETON, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in the care of prostate cancer, announced today...
Curium Initiates ECL
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
27 oct. 2021 02h15 HE | Curium
St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...
AB Science annonce q
AB Science annonce que les résultats de l'étude AB12003 du masitinib dans le cancer de la prostate ont été présentés lors du congrès annuel 2021 de l'American Urological Association
13 sept. 2021 12h04 HE | AB Science
COMMUNIQUE DE PRESSE LES RESULTATS DE L’ETUDE AB12003 DU MASITINIB DANS LE CANCER DE LA PROSTATE ONT ETE PRESENTES LORS DU CONGRES ANNUEL DE L’AMERICAN UROLOGICAL ASSOCIATION ET ONT ETE PUBLIES DANS...
AB Science announced
AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
13 sept. 2021 12h04 HE | AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12003 IN PROSTATE CANCER PRESENTED AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING WITH ABSTRACT PUBLISHED IN JOURNAL OF UROLOGY Paris, 13...
AB Science communiqu
AB Science communique ce jour une mise à jour du calendrier des résultats finaux de son étude de phase 3 du masitinib (AB12003) dans le traitement du cancer de la prostate métastatique
31 mars 2021 11h58 HE | AB Science
                                                                                                                                                                                               ...
AB Science provides
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
31 mars 2021 11h58 HE | AB Science
                                                                                                                                                                                                       ...
ProstaMend
ProstaMend Reviews: Negative Side Effects or Real Prostate Pills? 2021 Review
12 mars 2021 13h41 HE | 2021Review.com
Chicago, March 12, 2021 (GLOBE NEWSWIRE) -- ProstaMend is a daily prostate supplement that reduces its size and helps consumers reduce the number of times they go to the bathroom throughout their...
Shedir Pharma, an Italian Health and Wellness Company, Develops Nutritional Supplement for Prostate Functionality
27 déc. 2019 10h40 HE | Shedir Pharma
BOCA RATON, FL, Dec. 27, 2019 (GLOBE NEWSWIRE) -- If a man lives long enough, he will probably have prostate issues. Millions of men, especially those over 50, have enlarged prostates. Prostate...
Aquarius Surgical Technologies Announces Appointment of Mr. Gordon Willox as President & CTO, and the Closing of Funding Transaction
28 nov. 2018 04h00 HE | Surgical Lasers Inc.
TORONTO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Aquarius Surgical Technologies Inc. (ASTI – CSE) (“the Corporation”) is pleased to announce that Mr. Gordon Willox, has been appointed to the position of...
Exosome Diagnostics’
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
17 mai 2018 12h47 HE | Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...